KUALA LUMPUR, Feb 29 (Bernama) -- Medidata, a Dassault Systèmes company and provider of clinical trial solutions to the life sciences industry, has renewed its relationship with Thermo Fisher Scientific Inc’s PPD clinical research business.
“Over the past 15 years, we have built a valued connection with the PPD clinical research business to enhance visibility and decision-making during clinical trials.
“We look forward to working together to complete studies faster, boost drug development productivity, and ultimately bring life-changing treatments to patients sooner,” said Medidata executive vice president and head of global sales, Janet Butler.
According to Medidata in a statement, the agreement spans wide range of its solutions to enhance clinical trial efficiency.
The agreement features the Medidata Platform, as well as Medidata Adjudicate and additional Medidata Rave product offerings that support the PPD clinical research business in advancing its customers’ drug development programmes.
A key element of this relationship is the evolution of PPD TrueCast, a business solution powered by Medidata AI that shortens study timelines by combining patient recruitment and site performance data to deliver powerful predictive models and advanced analytics.
The company has collaborated with the PPD clinical research business since 2009 on over 1,000 clinical studies for biopharmaceutical and medical device companies across a broad range of therapeutic areas from oncology to vaccines.
-- BERNAMA
No comments:
Post a Comment